All the information on this page is sourced for Thomson Reuters Cortellis for Competitive Intelligence TM, find out more about Cortellis for Competitive Intelligence and take a free two week trial to see what Cortellis for Competitive Intelligence can do for you.

Content last updated November 15, 2011.

Bevacizumab (Avastin) is a humanized mAb against VEGF for iv use and just one of the many drugs covered in Thomson Reuters Cortellis for Competitive Intelligence. In addition to the Drug Report summary information below, in Cortellis for Competitive Intelligence, you will see the drug overview information, news, deals, development status, literature evaluations, SWOT analysis, patent position and sales and market share data. There are over 40,000 of these Drug Reports in Cortellis for Competitive Intelligence.

Cortellis for Competitive Intelligence combines the same premier information used by the world's leading pharmaceutical companies from products such as Thomson Reuters Pharma TM and Thomson Reuters Partnering TM (formerly IDDB). Featuring daily updates and timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

All Cortellis for Competitive Intelligence content is subject to an exhaustive editorial review process conducted by scientists, Pharma professionals, regulatory experts, and generics specialists. It is also updated regularly, so you get the most accurate and up-to-date information on the pharmaceutical data that matters to you.

Take a two week trial of Cortellis for Competitive Intelligence and see what it can do for you.

SUMMARY

Drug Namebevacizumab
CompanyGenentech Inc (Roche Holding AG)
Highest Dev StatusLaunched
FDA ApprovedGlioblastoma Multiforme Of Brain, Recurrent, Progressive Disease Following Prior Therapy (Adult), Metastatic Breast Cancer, Her2-Negative, As First-Line Therapy In Combination With Paclitaxel (Adult), Metastatic Colorectal Cancer, First- Or Second-Line Therapy, In Combination With 5-Fluorouracil-Based Chemotherapy (Adult), Metastatic Renal Cell Carcinoma, In Combination With Interferon Alfa (Adult), Nonsquamous Non-Small Cell Lung Cancer, Recurrent Or Metastatic, Unresectable, Locally Advanced, First-Line Treatment In Combination With Paclitaxel And Carboplatin (Adult)
Therapy AreasNeuroendocrine tumor; Age related macular degeneration; Mesothelioma; Small-cell lung cancer; Non-small-cell lung cancer; Stomach tumor; Myelodysplastic syndrome; Biliary cancer; Endometroid carcinoma; Renal cell carcinoma; Hepatocellular carcinoma; Multiple myeloma; Sarcoma; Melanoma; Fallopian tube cancer; Glioblastoma; Pancreas tumor; Carcinoid tumor; Peritoneal tumor; B-cell lymphoma; Non-Hodgkin lymphoma; Gastrointestinal stromal tumor; Hormone refractory prostate cancer; Breast tumor; Genitourinary tract tumor; Head and neck tumor; Colon tumor; Ovary tumor; Colorectal tumor
ActionsVEGF ligand inhibitor; Anticancer monoclonal antibody; Angiogenesis inhibitor
TechnologiesMonoclonal antibody humanized; Intravenous formulation; Infusion; Biological therapeutic
TargetVEGF ligand
Update date15-NOV-2011
Reason for updateMinor editorial amendment